The median overall survival for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains less than one year despite a wide armamentarium of therapeutic approaches including anti-EGFR antibody Cetuximab [2, 3]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.